The short version of storage stability fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
The data supporting this theory are limited and contradictory, since both increased intestinal permeability and normal permeability have been documented in people with autism. Studies with mice provide some support to this theory and suggest the importance of intestinal flora, demonstrating that the normalization of the intestinal barrier was associated with an improvement in some of the autism-like behaviors. Studies on subgroups of people with autism showed the presence of high plasma levels of zonulin, a protein that regulates permeability opening the "pores" of the intestinal wall, as well as intestinal dysbiosis (reduced levels of Bifidobacteria and increased abundance of Akkermansia muciniphila, Escherichia coli, Clostridia and Candida fungi that promote the production of proinflammatory cytokines, all of which produces excessive intestinal permeability. This allows passage of bacterial endotoxins from the gut into the bloodstream, stimulating liver cells to secrete tumor necrosis factor alpha (TNFα), which modulates blood–brain barrier permeability. Studies on ASD people showed that TNFα cascades produce proinflammatory cytokines, leading to peripheral inflammation and activation of microglia in the brain, which indicates neuroinflammation. In addition, neuroactive opioid peptides from digested foods have been shown to leak into the bloodstream and permeate the blood–brain barrier, influencing neural cells and causing autistic symptoms.
In Nebraska, the company is affiliated with the Liz's Legacy Cancer Fund "BK Beat Cancer for Kids" program at the UNMC Eppley Cancer Center at the University of Nebraska Medical Center in Omaha. In the Pittsburgh region, it funded the establishment of the Burger King Cancer Caring Center, a support organization for the families and friends of cancer patients.
=== Sleep problems === Sleep disturbances are extremely common in fibromyalgia and may occur in up to 90% of patients. These disturbances frequently include non-restorative sleep, morning tiredness, and daytime somnolence. Although patients often report poor sleep quality, insomnia itself is not considered a typical or defining feature of fibromyalgia. Instead, individuals may obtain a normal duration of sleep but still wake feeling unrefreshed due to abnormalities in sleep architecture and pain-related disruptions in restorative sleep stages. A meta-analysis compared quantitative and qualitative sleep metrics in people with fibromyalgia and healthy people. Individuals with fibromyalgia reported lower sleep quality and efficiency, longer wake time after sleep onset, shorter sleep duration, lighter sleep, and greater difficulty initiating sleep, both quantitatively and qualitatively. Improving sleep quality can help people with fibromyalgia manage pain.
Sources: en.wikipedia.org
=== Response to pollution and environmental stress === Historical records indicate that X. parietina persisted in London despite severe air pollution, even when many other lichens disappeared. Mid-20th century mapping studies revealed that its distribution correlated with areas of moderate sulphur dioxide concentrations, but it was absent from the most polluted zones of central London, suggesting that while resistant to airborne contaminants, it has an upper tolerance limit. However, it is sensitive to certain pollutants, as demonstrated after the Torrey Canyon oil spill, when oil contamination and toxic dispersants caused widespread mortality on coastal rocks. Affected thalli lost their characteristic orange pigmentation, indicating chemical damage that interfered with enzymatic and protein activity, ultimately leading to detachment from the rock surface. The dispersant BP 1002, used during cleanup efforts, was later found to be highly toxic to marine life and coastal lichens. In X. parietina, its surfactant components disrupted algal cell membranes, reducing photosynthetic activity and accelerating thallus deterioration. Pollution affects both the population structure and development of X. parietina. There has been a decline in population density with increasing pollution levels; one study documented approximately 47 thalli per tree in lightly polluted zones, compared to 12 in moderately polluted areas and 9 in severely polluted regions. In unpolluted environments, the lichen completes its full life cycle, reaching maturity and old age.
===== ICONIC-LEAD ===== The ICONIC-LEAD study is a phase III, randomized, double-blind, placebo-controlled trial evaluating icotrokinra versus placebo in patients with moderate to severe plaque psoriasis. The study met its co-primary endpoints, with 74% of patients achieving clear or almost clear skin (IGA 0/1) at week 24.
A notable and unusual building in the area is the so-called "Fetta di Polenta" (lit. 'polenta slice'), formerly known as Casa Scaccabarozzi. This building is where Corso San Maurizio meets Via Giulia di Barolo, and it is one of the most peculiar examples of Turin architecture: a thin trapezoid 27 m (89 ft) wide on Via Giulia Di Barolo, 5 m (16 ft) on Corso San Maurizio and just 0.70 m (2 ft 4 in) wide on the opposite end. It was designed in 1840 by Alessandro Antonelli for his wife, Francesca Scaccabarozzi. The curious name comes from the shape of the palace, which resembles a "slice of polenta", and also because it is painted with an ochre colour. In the surroundings, in Via Vanchiglia 8 (although in downtown and not really in Vanchiglia anymore), there is another trapezoid house, albeit with less extreme design: similarly, this building is nicknamed "Fetta di Formaggio" (lit. 'cheese slice'), built in 1832 for the rich Marchese Birago di Vische by the architect Antonio Talentino. Other notable buildings are the town public baths, eclectic building built in 1905 (Corso Regina Margherita crossing Via Vanchiglia), and theTeatro della Caduta theatre, opened in 2003 in Via Michele Buniva 23, which with its 45 seats is the smallest theatre in Turin and among the smallest theatres in Europe. In Corso Regina Margherita, another notable building is the former Opera pia Reynero, a charitable organisation. The building was built in 1892.
A position of a codon is said to be a n-fold degenerate site if only n of four possible nucleotides (A, C, G, T) at this position specify the same amino acid. A nucleotide substitution at a 4-fold degenerate site is always a synonymous mutation with no change on the amino acid. A less degenerate site would produce a nonsynonymous mutation on some of the substitutions. An example (and the only) 3-fold degenerate site is the third position of an isoleucine codon. AUU, AUC, or AUA all encode isoleucine, but AUG encodes methionine. In computation, this position is often treated as a twofold degenerate site. A position is said to be non-degenerate if any mutation at this position changes the amino acid. For example, all three positions of methionine's AUG are non-degenerate, because the only codon coding for methionine is AUG. The same goes for tryptophan's UGG. There are three amino acids encoded by six different codons: serine, leucine, and arginine. Only two amino acids are specified by a single codon each. One of these is the amino-acid methionine, specified by the codon AUG, which also specifies the start of translation; the other is tryptophan, specified by the codon UGG.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.